146 related articles for article (PubMed ID: 22843619)
1. Synergistic effect of heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin and X-rays, but not carbon-ion beams, on lethality in human oral squamous cell carcinoma cells.
Musha A; Yoshida Y; Takahashi T; Ando K; Funayama T; Kobayashi Y; Negishi A; Yokoo S; Nakano T
J Radiat Res; 2012 Jul; 53(4):545-50. PubMed ID: 22843619
[TBL] [Abstract][Full Text] [Related]
2. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
[TBL] [Abstract][Full Text] [Related]
3. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.
Watanabe G; Behrns KE; Kim JS; Kim RD
Cancer Chemother Pharmacol; 2009 Aug; 64(3):433-43. PubMed ID: 19082595
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
8. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
Russell JS; Burgan W; Oswald KA; Camphausen K; Tofilon PJ
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3749-55. PubMed ID: 14506167
[TBL] [Abstract][Full Text] [Related]
10. [Effects of HSP90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901].
Chen M; Xu J; Zhao J
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):271-5. PubMed ID: 23443787
[TBL] [Abstract][Full Text] [Related]
11. Effect of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on Akt protein expression is more effective in head and neck cancer cell lineages that retain PTEN protein expression.
Pontes FSC; Pontes HAR; de Souza LL; de Jesus AS; Joaquim AMC; Miyahara LAN; Fonseca FP; Pinto Junior DS
J Oral Pathol Med; 2018 Mar; 47(3):253-259. PubMed ID: 29297949
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Noguchi M; Yu D; Hirayama R; Ninomiya Y; Sekine E; Kubota N; Ando K; Okayasu R
Biochem Biophys Res Commun; 2006 Dec; 351(3):658-63. PubMed ID: 17083915
[TBL] [Abstract][Full Text] [Related]
13. TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.
Lee Y; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Mol Cancer Ther; 2017 Jan; 16(1):16-24. PubMed ID: 28062703
[TBL] [Abstract][Full Text] [Related]
14. In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.
Ochel HJ; Gademann G
Anticancer Res; 2006; 26(3A):2085-91. PubMed ID: 16827149
[TBL] [Abstract][Full Text] [Related]
15. The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.
Zhang J; Zheng Z; Zhao Y; Zhang T; Gu X; Yang W
Clin Exp Med; 2013 Nov; 13(4):323-8. PubMed ID: 22955701
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
Li Y; Zhang T; Schwartz SJ; Sun D
Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
[TBL] [Abstract][Full Text] [Related]
17. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
18. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Banerji U; Sain N; Sharp SY; Valenti M; Asad Y; Ruddle R; Raynaud F; Walton M; Eccles SA; Judson I; Jackman AL; Workman P
Cancer Chemother Pharmacol; 2008 Oct; 62(5):769-78. PubMed ID: 18193424
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
20. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
